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Abstract As β3-adrenoceptor agonists metamorphose from
experimental tools into therapeutic drugs, it is vital to
obtain a comprehensive picture of the cell and tissue
functions mediated by this receptor subtype in humans.
Human tissues with proven functions and/or a high
expression of β3-adrenoceptors include the urinary bladder,
the gall bladder, and other parts of the gastrointestinal tract.
While several other β3-adrenoceptor functions have been
proposed based on results obtained in animals, their
relevance to humans remains uncertain. For instance, β3-
adrenoceptors perform an important role in thermogenesis
and lipolysis in rodent brown and white adipose tissue,
respectively, but their role in humans appears less significant.
Moreover, the use of tools such as the agonist BRL 37344
and the antagonist SR59230A to demonstrate functional
involvement of β3-adrenoceptors may lead in many cases
to misleading conclusions as they can also interact with
other β-adrenoceptor subtypes or even non-adrenoceptor
targets. In conclusion, we propose that many responses
attributed to β3-adrenoceptor stimulation may need re-
evaluation in the light of the development of more selective
tools. Moreover, findings in experimental animals need to
be extended to humans in order to better understand the
potential additional indications and side effects of the β3-
adrenoceptor agonists that are beginning to enter clinical
medicine.
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While β1-a n dβ2-adrenoceptor ligands have long assumed
key roles in the treatment of various conditions such as
coronary heart disease or obstructive airway disease,
compounds acting on β3-adrenoceptors are only now
undergoing a metamorphosis from experimental tools into
therapeutic drugs, e.g., in the treatment of the overactive
bladder syndrome (Chapple et al. 2008). The introduction
of a new class of drugs is exciting but also generates
uncertainty about possible safety and tolerability issues
associated with this drug class. The determination of tissues
where β3-adrenoceptors play a role has long been ham-
pered by the lack of highly selective agonists and
antagonists (Vrydag and Michel 2007). In this issue of the
journal, Mori et al. report β3-adrenoceptor-mediated vaso-
dilatation in rat retinal blood vessels in vivo (Mori et al.
2010). Theirstudyexpandsourknowledgeoftissuefunctions
mediated by β3-adrenoceptors but also highlights the
methodological challenges in this field. Against this back-
ground, we will briefly mention those tissues in which
functional β3-adrenoceptors have been demonstrated with
various degrees of certainty and discuss the implications for
the therapeutic use of agonists acting at these receptors. This
discussion will largely be based on examples and does not
attempt to be comprehensive. Where possible, we will
primarily focus on human tissues. Fields that have been
extensively reviewed recently will only be mentioned briefly.
At the mRNA level, β3-adrenoceptors have been found
in a range of human tissues including brown and white
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DOI 10.1007/s00210-010-0529-2adipose tissue, small and large intestine, gall bladder,
urinary bladder, and brain with low levels in heart and
colon; no mRNAwas detected in quadriceps and abdominal
muscle, liver, lung, kidney, thyroid, or lymphocytes
(Berkowitz et al. 1995; Krief et al. 1993; Otsuka et al.
2008) .S t u d i e si nr a t sh a v ed e t e c t e dβ3-adrenoceptor
mRNA mainly in brown and white adipose tissue, in
various segments of the gastrointestinal tract, and in the
urinary bladder (Cohen et al. 1995; Evans et al. 1996;
Fujimura et al. 1999; Roberts et al. 1999), but as in humans,
it is also present in brain (Summers et al. 1995). Antibody-
b a s e dd e t e c t i o no fβ3-adrenoceptor expression at the
protein level has been reported in human gall bladder,
colon, prostate, right atrium, and gastrocnemius muscle,
whereas no labelling was detected in lung, left ventricle,
appendix, uterus, or thyroid (Chamberlain et al. 1999).
Detection inadipose tissue frombreast, perirenal, and axillary
sites proved inconclusive due to problems of interpreting
labelling of the thin-walled adipocytes (Chamberlain et al.
1999). While this study provided some validation of
antibody selectivity, more recent data raise doubts about
the validity of many other receptor antibodies (Michel et al.
2009), including those acting on β-adrenoceptor subtypes
(Hamdani and van der Velden 2009; Pradidarcheep et al.
2009).
Based on rodent data, β3-adrenoceptors have long been
associated with the promotion of lipolysis in adipocytes,
mostly in brown adipose tissue. These findings have
prompted drug discovery programmes in the fields of
obesity and type 2 diabetes that have yielded disappointing
results (Arch 2008) at least partly due to the distinct
difference between the rodent and human pharmacophore,
which led to the development of several drugs (e.g., BRL
37,344, CL 316,243) that were highly effective and
selective in rodents (Arch et al. 1984; Bloom et al. 1992)
but with little selectivity or efficacy in humans. The
explanation that was adopted initially was that β3-
adrenoceptors play an important role in rodent lipolysis
but have a much smaller role in humans (Arner et al. 1991;
Thomas and Liggett 1993). However, recent findings
question this assumption and strongly suggest that there
is metabolically active brown fat in humans (Nedergaard
et al. 2007). Nevertheless, there is still debate as to
whether and to what extent the metabolic effects of
catecholamines in humans are mediated through β1-o r
β3-adrenoceptors (Nedergaard and Cannon 2010). If
anything, the metabolic effects of β3-adrenoceptor ago-
nists are likely to be beneficial in humans, but whether the
extent of such effects is clinically relevant cannot be
determined with certainty based upon the present data.
In contrast, β3-adrenoceptors play an important role in
the urinary bladder of humans, likely to an even greater
extent than in some animal species (Michel and Vrydag
2006). Within the urinary bladder, they mediate smooth
muscle relaxation (Michel and Parra 2008), but they may
also affect the function of the urothelium (Masunaga et al.
2010; Otsuka et al. 2008) and afferent nerves (Aizawa et al.
2010). Accordingly, the β3-adrenoceptor agonist mirabe-
gron, previously known as YM-178, has shown efficacy in a
clinical proof of concept study in patients with overactive
bladder (Chapple et al. 2008) and is now in the late stages of
clinical development for this indication. β3-Adrenoceptors
may also play a role in the relaxation of human ureter (Park
et al. 2000; Tomiyama et al. 2003; Wanajo et al. 2004),
urethra (Yamanishi et al. 2003), and penis smooth muscle
(Cirino et al. 2003).
β3-Adrenoceptors have also been proposed to play a role
in the cardiovascular system, but the evidence for their role
remains equivocal, particularly in humans. Thus, several
studies have proposed functional β3-adrenoceptors in the
rodent heart, which in contrast to β1- and β2-adrenoceptors
may mediate negative inotropic effects (Rozec and Gauthier
2006). β3-Adrenoceptors mediating positive inotropic
effects have been proposed in the human heart (Gauthier
et al. 1996; Pott et al. 2003; Skeberdis et al. 2008), but
other studies have failed to demonstrate this finding (Christ
et al. 2010; Ikezono et al. 1987). On the other hand, reports
of vasodilatation mediated by β3-adrenoceptors are more
consistent (Guimaraes and Moura 2001; Rozec and
Gauthier 2006), although the vast majority of these findings
come from experimental animals that exhibit major inter-
tissue and interspecies differences that make extrapolation
to humans difficult. The study by Mori et al. (2010) adds
interesting information in this regard as it demonstrates β3-
adrenoceptor-mediated vasodilatation in retinal vessels
based on drugs with validated selectivity at human subtypes
such as the antagonist L-748,337. On the other hand, the
same study also shows that concomitant systemic vasodi-
latation by putative β3-adrenoceptor agonists such as BRL
37,344 or CL 316,243, assessed as blood pressure
reductions, is largely, if not completely, mediated by β1-
or β2-adrenoceptors, being inhibited by propranolol but not
L-748,337 (Mori et al. 2010). While these data suggest that
there may be therapeutic potential for β3-adrenoceptor
agonists in the treatment of diabetic retinopathy, it remains
to be confirmed whether this can be extrapolated to
humans. Moreover, based upon the expression of functional
β3-adrenoceptors in retinal endothelial cells (Steinle et al.
2003), it remains to be determined whether vasodilatation
of retinal vessels primarily involves smooth muscle or
endothelium. Potential effects of β3-adrenoceptor agonists
on the systemic circulation and the heart remain to be
studied in more detail in humans, particularly with regard to
a possible risk of hypotension and/or arrhythmia.
In line with the β3-adrenoceptor mRNA expression in
the gastrointestinal tract of rats (Evans et al. 1996) and
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proposed the presence of functional receptors (largely based
on rat and guinea pig studies) in the esophagus (de Boer et
al. 1995; Lezama et al. 1996; Oostendorp et al. 2004),
stomach (McLaughlin and MacDonald 1991) (Cohen et al.
1995; Horinouchi and Koike 2001), and small and large
intestine (Bond and Clarke 1988;H o e ye ta l .1996;
Horinouchi and Koike 2001; Roberts et al. 1997; Roberts
et al. 1999). Generally, β3-adrenoceptor agonists mediate
smooth muscle relaxation in these tissues including human
colon (Roberts et al. 1997). Accordingly, in in vivo studies,
β3-adrenoceptor agonists slowed transit time in wild-type
but not β3-adrenoceptor knockout mice (Fletcher et al.
1998). On the other hand, the β3-adrenoceptor agonist
solabegron did not significantly alter human colonic transit
during a 7-day administration (Grudell et al. 2008).
Additional effects on the gastrointestinal tract included
reports of enhanced gastric blood flow (Kuratani et al.
1994) and reduced gastric acid secretion (Coruzzi and
Bertaccini 1997), leading to protection against gastric ulcers
in experimental animals. Moreover, a β3-adrenoceptor
agonist was reported to improve colitis in a rat model
(Vasina et al. 2008). Functional β3-adrenoceptors have also
been proposed in the gall bladder (Oriowo and Thulesius
1999) and in pancreas (Atef et al. 1996). Based on these
results, some β3-adrenoceptor agonists may cause consti-
pation, but they may also have protective effects against
gastric ulcers and/or colitis.
Outside the abovementioned systems, functional β3-
adrenoceptors have also been proposed in myometrium
(Bardou et al. 2000; Bardou et al. 2007; Rouget et al.
2004). Whether responses to β3-adrenoceptor agonists are
less prone to desensitization than β2-adrenoceptor agonists
when used for tocolytic treatment remains to be established.
β3-Adrenoceptors were also proposed in skeletal muscle
(Roberts et al. 1993) and in the brain, where they
apparently can mediate important effects in animal models
of memory, anxiety, and depression (Gibbs et al. 2010;
Hutchinson et al. 2007; Stemmelin et al. 2008). The latter
effect may become useful therapeutically for agonists with
good penetration into the brain.
Of note, most of the above studies have relied on the use
of agonists and/or antagonists with little selectivity for this
subtype such as SR59230A (Vrydag and Michel 2007). As
highlighted by the study in this issue (Mori et al. 2010) and
other recent data (Ngala et al. 2009), agonists such as BRL
37,344 or CL 316,243 can activate not only β3-adrenocep-
tors but also other β-adrenoceptor subtypes and possibly
nonadrenoceptor targets. While SR59230A has relatively
high affinity for β3-adrenoceptors in contrast to many
classical β-adrenoceptor antagonists, it has at least
similar, if not slightly higher, affinity for human β1- and
β2-adrenoceptors and can be a partial agonist at β3-
adrenoceptors (Vrydag and Michel 2007). Therefore, most
of the above studies have to be interpreted carefully in the
light of the selectivity of the tools on which they are based.
At present, L-748,337 appears to be the only widely
available antagonist with a well-validated selectivity for
human β3-adrenoceptors. Thus, several tissue functions that
have until now been assigned to β3-adrenoceptors may
require confirmation with these more selective tools.
Another issue is that findings in rodents and other
experimental animals are an important step but may not
necessarily reliably predict findings in humans. For
example, β3-adrenoceptors appear to be the predominant
if not the only subtype-mediating relaxation of the human
urinary bladder, whereas in rats and some other species, this
function involves at least one other subtype (Michel and
Vrydag 2006). Conversely, β3-adrenoceptors play an
important role in rodent lipolysis, but their role is much
less clear-cut in humans (Arch 2008).
In addition to off-target effects due to the presence of β3-
adrenoceptors in tissues that are not being targeted for a
therapeutic effect, it is also increasingly evident that drugs
acting at this receptor cannot be classified simply as
agonists, partial agonists, or antagonists, and that ligands
can induce unique ligand-specific receptor conformations
that can result in differential activation of particular signal
transduction pathways (Urban et al. 2007), the phenomenon
known (amongst other terms) as ligand-directed signaling
bias. At the β3-adrenoceptor, L-748,337 is a competitive
antagonist for cAMP accumulation but has high agonist
potency and efficacy for ERK1/2 phosphorylation. Zinterol,
which has agonist properties at the human β3-adrenoceptor
(Hutchinson et al. 2006), has high efficacy for cAMP
accumulation but lower efficacy than L-748,337 for both
ERK1/2 and p38 MAPK phosphorylation (Sato et al. 2008).
A similar reversal of efficacy was also seen with CL
316,243 and SR59230A acting at the mouse β3-adreno-
ceptor (Sato et al. 2007). When the functional readout is
cAMP, CL 316,243 is a full agonist and SR59230A either a
partial agonist or antagonist depending on the level of
receptor expression. In the identical cells, but using
extracellular acidification rate as the functional measure,
both CL 316,243 and SR59230A are full agonists at all
levels of receptor expression. Further analysis with selec-
tive MAPK inhibitors confirmed that SR59230A has much
higher efficacy than CL 316,243 for MAPK signaling.
These examples of reversal of efficacy provide strong
support for the concept of ligand-directed signaling (Evans
et al. 2010) and suggest that other factors may have to be
taken into account when optimizing clinical efficacy of new
drugs acting at β3-adrenoceptors.
A final aspect of the study by Mori et al. (2010) merits
comment. They show that β2-adrenoceptor-mediated vaso-
dilatation in the general circulation apparently undergoes
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mediated vasodilatation in retinal vessels does not. Indeed,
the expression and function of β1- and β2-adrenoceptors
undergoes extensive desensitization in disease states such
as heart failure (Brodde 2007) or upon agonist treatment,
e.g., in the context of tocolysis (Frambach et al. 2005),
whereas β3-adrenoceptor responses may be much less
susceptible to such regulation in most but not all cases
(Chaudhry and Granneman 1994; Vrydag et al. 2009).
In conclusion we propose that many responses attributed
to β3-adrenoceptor stimulation may need revalidation using
truly selective tools. Moreover, findings in experimental
animals need to be extended to humans in order to better
understand the safety profile of β3-adrenoceptor agonists
likely to enter clinical medicine soon.
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